Suspension of trading
Valuation Amicus Therapeutics, Inc.
Stocks
FOLD
US03152W1099
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-04-24 EDT
|
5-day change | 1st Jan Change | ||
| 14.49 USD | +0.21% |
|
-.--% | +1.76% |
| 05-05 | BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says | MT |
| 04-28 | Amicus Therapeutics, Inc.(NasdaqGM:FOLD) dropped from S&P Global BMI Index | CI |
Company Valuation: Amicus Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 6,017 | 3,218 | 3,430 | 4,161 | 2,815 | 4,405 |
| Change | - | -46.51% | 6.59% | 21.31% | -32.36% | 56.48% |
| Enterprise Value (EV) 1 | 5,975 | 3,176 | 3,589 | 4,320 | 3,008 | 4,553 |
| Change | - | -46.85% | 13% | 20.38% | -30.36% | 51.35% |
| P/E | -21.6x | -12.5x | -14.9x | -27.6x | -51.1x | -162x |
| PBR | 21.1x | 10.5x | 27.9x | 26x | 14.5x | 16.1x |
| PEG | - | 0.9x | 1.3x | 0.7x | 0.8x | 3.1x |
| Capitalization / Revenue | 23.1x | 10.5x | 10.4x | 10.4x | 5.33x | 6.94x |
| EV / Revenue | 22.9x | 10.4x | 10.9x | 10.8x | 5.69x | 7.18x |
| EV / EBITDA | -25.4x | -16.4x | -18x | -65.8x | 70.6x | 109x |
| EV / EBIT | -24.5x | -15.9x | -17.6x | -58.8x | 88.3x | 132x |
| EV / FCF | -43.4x | -37.4x | -38.1x | -167x | 557x | 95.2x |
| FCF Yield | -2.3% | -2.68% | -2.63% | -0.6% | 0.18% | 1.05% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -1.069 | -0.9228 | -0.82 | -0.5136 | -0.1843 | -0.0879 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 260.9 | 305.5 | 329.2 | 399.4 | 528.3 | 634.2 |
| EBITDA 1 | -235 | -193.7 | -199.1 | -65.62 | 42.61 | 41.95 |
| EBIT 1 | -243.9 | -199.9 | -204.4 | -73.49 | 34.06 | 34.49 |
| Net income 1 | -276.9 | -250.5 | -236.6 | -151.6 | -56.11 | -27.11 |
| Net Debt 1 | -41.54 | -42.37 | 158.5 | 158.9 | 193.7 | 148.8 |
| Reference price 2 | 23.09 | 11.55 | 12.21 | 14.19 | 9.42 | 14.24 |
| Nbr of stocks (in thousands) | 260,588 | 278,646 | 280,945 | 293,257 | 298,806 | 309,309 |
| Announcement Date | 3/1/21 | 2/24/22 | 3/1/23 | 2/28/24 | 2/19/25 | 2/20/26 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 4.55B | |
| 31.39x | 5.65x | 16.94x | 1.03% | 45.81B | |
| -20.96x | 242.19x | -22.49x | -.--% | 43.91B | |
| 34.73x | 3.34x | 14.43x | -.--% | 44.39B | |
| 45.39x | 5.23x | 28.64x | -.--% | 39.4B | |
| 26.93x | 8.12x | 20.58x | 0.42% | 31.26B | |
| 35.28x | 5.79x | 26.31x | -.--% | 17.32B | |
| 24.5x | 2.13x | 9.21x | 1.09% | 14.73B | |
| 73x | 3.87x | 15.01x | -.--% | 13.03B | |
| Average | 31.28x | 34.54x | 13.58x | 0.32% | 28.27B | |
| Weighted average by Cap. | 26.47x | 46.77x | 11.96x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FOLD Stock
- Valuation Amicus Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
